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CyclinA2 is best known for the regulation of the eukaryotic cell cycle through binding and 
activating CDK2. The role of the CyclinA2-CDK2 protein complex as a regulator of the S and G2 
phases of the cell cycle is well characterized, but additional functions of these proteins when acting 
independently is more enigmatic. While both proteins operate separately in DNA damage repair 
pathways, CyclinA2 has additionally been implicated in neuronal development and maintenance, 
working apart from CDK2. Development and application of CyclinA2-specific inhibitors will 
elucidate the protein’s specific roles in the neuron. Prior computational modeling done by Dr. 
Stephanie Kim identified four potential small molecule inhibitors which were intended to act on 
an allosteric site of CyclinA2, and were confirmed to be inhibitory with an assay testing the activity 
of the CyclinA2-CDK2 complex. Our aim was to determine where these inhibitors interact with 
the CyclinA2-CDK2 complex using 2D 1H-15N NMR spectroscopy. Comparison of the NMR 
spectra of CDK2 in the presence of ATP and three of the inhibitors indicated that CDK2 interacts 
with these inhibitors independently of CyclinA2. Furthermore, similarities in the titration spectra 
of the compounds and ATP suggest that these molecules may act competitively at the ATP binding 
site. Efforts to determine how CyclinA2 or the CyclinA2-CDK2 complex interacted with the 
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The eukaryotic cell cycle is imperative in embryological development, tissue regeneration, 
and growth. Cyclin-dependent kinases (CDK) and their regulatory counterparts, Cyclins, are 
responsible for checkpoint mediation throughout the cell cycle in the G1, S, G2, and M phase 
(Figure 1A). Upon complex formation with a cognate CDK, each member of the cyclin family 
regulates specific aspects of transcription and cellular replication (Figure 1B). Cyclins are then 
tagged for ubiquitin-mediated proteolysis, resulting in a decrease in the corresponding kinase 
activity (Brown et al., 1999).  
 
Figure 1: Cyclin-CDK complexes regulate the cell cycle. A. The cell cycle includes both 
interphase and mitosis. Interphase can be further divided into G1 phase, S phase, and G2 phase. 
The checkpoints marked G1-S and G2-M are regulated by Cyclin-CDK complexes. B. The 
distribution of Cyclin-CDK complexes throughout the cell cycle is visualized. Different 
combinations of Cyclins and CDKs phosphorylate key proteins at each checkpoint. Figure 




The CyclinA2-CDK2 complex is responsible for initiation of DNA replication in the S 
phase, specifically via the phosphorylation of key proteins (Kanakkanthara et al., 2016; Li et al., 
2015). Both CDK2 and CyclinA2 are known to interact with other associated proteins, leading to 
various cellular functions. CDK2 is involved in chromatin remodeling and apoptosis, and is 
essential in instigating the DNA Repair Response (DRR) network to repair DNA damage due to 
radiation, oxidative damage, and chemical mutagens (Liu et al., 2020). The C-terminus of 
CyclinA2, which shows low sequence homology with other members of the Cyclin family, binds 
to the UTR of Mre11 transcripts, promoting translation of Mre11, a protein instrumental in repair 
of DNA double stranded breaks. Mice unable to regulate normal concentrations of cellular 
CyclinA2 were shown to be more likely to develop tumors due to a lack of this ability 
(Kanakkanthara et al., 2016).  
Additionally, CyclinA2 has been shown to be important in neuronal development and 
functioning. In neural cells obtained from mice, a deficit of CyclinA2 resulted in neurological 
developmental impediments (Otero et al., 2014). In addition, the decreased regulation of 
chromosomal duplication and hindered DNA repair mechanisms in embryogenesis caused 
increased apoptosis and lengthened the cell cycle, resulting in delayed proliferation of the forebrain 
(Gygli et al., 2016). Furthermore, different isoforms of CyclinA2 have been identified in the brain 
during different points in development. In embryonic mice, the predominant form was full length 
CyclinA2 protein, indicating importance in neural proliferation; while a truncated isoform without 
the N-terminus was determined to be present in adult mice, suggesting a role in neuronal 
maturation (Otero et al., 2014). Adult mice shown to be deficient in CyclinA2 displayed learning 
and memory deficits, consistent with an inability to repair double stranded DNA breaks in mature 
neurons in the hippocampus (Gygli et al., 2016). CDK2 is not required for hippocampal 
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neurogenesis and maintenance, and CDK2-deficient mice displayed no significant difference in 
proliferation of neuron-progenitor cells or differentiation (Vandenbosch et al., 2008).  
Structurally, CyclinA2 is composed of twelve ɑ-helices. Much like other members of the 
Cyclin family, CyclinA2 contains a Cyclin fold, two structurally identical sets of five ɑ-helices 
separated by a linker of five amino acids. These ɑ-helices pack loosely in a globular structure 
(Figure 2A). Another structural feature of CyclinA2 is the Cyclin box, which mediates complex 
formation with CDK2 (Jeffrey et al., 1995). CDK2 is a globular protein, composed of two lobes 
with an ATP and Cyclin binding cleft in between (Figure 2A, 2B). Other components involved in 
complex formation involve the PSTAIRE helix, which interacts with the Cyclin box and is thought 
to be responsible for specificity; and the T-loop, which blocks the binding cleft in the absence of 
Cyclin (Jeffrey et al., 1995). Conformational changes in the presence of ATP and CyclinA2 include 
rotation of the PSTAIRE helix, resulting in a tighter protein structure of CDK2, and the movement 
of the T-loop away from the bi-lobar protein body (Figure 2A). This movement exposes the ATP 
binding cleft and conserved phosphorylation site at Thr160, and triggers CDK2 activation. 
Compared to the conformational changes undergone by CDK2, the structure of CyclinA2 remains 
relatively the same, with the Cyclin box and N terminal helices forming most of the interactions 






Figure 2: The Structure of CDK2 and the CyclinA2-CDK2 complex. A. Formation of the 
CyclinA2-CDK2 complex. CyclinA2 (PDB id 1FIN) and CDK2 (PDB id 1HCK) are pictured 
independently. Structural motifs of CDK2 which have undergone significant conformational 
changes upon binding to CyclinA2 is highlighted in cyan (PDB id 1OL1). These elements include 
shifting of the PSTAIRE helix and T-loop to facilitate phosphorylation activity. Figure from Li et 
al., 2015. B. Ribbon structure of CDK2 complexed with ATP and a magnesium ion. The bi-lobal 
structure, Cyclin box, and ATP binding cleft are indicated. C. A closer image of ATP-bound 
CDK2. ATP and the complexed magnesium ion can be seen buried in the binding cleft. Both B 




As both CyclinA2 and CDK2 have various roles in cell cycle regulation, DNA repair, and 
embryogenesis, development of Cyclin and CDK inhibitors is of great pharmacological interest. 
The vast majority of CDK inhibitors compete with ATP at the ATP binding site. Due to the highly 
conserved nature of the ATP binding pocket, current inhibitors are poor candidates as they lack 
specificity within the CDK family. Therefore, development of inhibitors that target allosteric sites 
on CDKs or the Cyclin binding partner would enable a greater degree of specificity. To our best 
knowledge, there are no inhibitors that specifically target CyclinA2, and there is only one inhibitor 
that targets an allosteric site on CDK2 (Faber et al., 2020).  
  The role of CyclinA2 in brain development has not yet been completely understood, and 
elucidating its functions without CDK binding partners is critical. Development of a CyclinA2 
specific inhibitor would enable further investigation of the roles of CyclinA2 in the brain as well 
other capacities where it functions independently, and would be of great pharmacological interest. 
Computational structural modeling determined a potential allosteric binding site on CyclinA2, and 
identified several compounds which had inhibitory potential. Bioluminescence enzymatic assays 
were implemented measuring the activity of the CyclinA2-CDK2 complex, and four compounds 
were determined to be inhibitory in micromolar to nanomolar concentrations (Figure 3) (Stephanie 
Kim et al., 2020). However, as inhibitory capability was determined by measuring the kinase 
activity of the CyclinA2-CDK2 complex, it was unclear whether the inhibitors were binding to 
CyclinA2, or CDK2. Using Nuclear Magnetic Resonance (NMR) spectroscopy and native Mass 
Spectrometry, we aim to identify where these molecular inhibitors interact with the complex. By 
recording 15N-HSQC NMR data and measuring chemical shift perturbations of the amide 
backbone signals, which indicate ligand-protein interactions, we confirm that all three inhibitors 
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which were tested interact with CDK2, and potentially inhibit activity through binding at the ATP 
binding site.  
 
 
Figure 3: Designed molecular inhibitors of CDK2. The four inhibitors determined to bind to the 
allosteric sit on CyclinA2 are pictured above. The NSC identification numbers are listed below 
each compound, as are the IC50 values, determined by the in vitro biochemical assay.  
 
 
2. Methods and Materials 
2.1. Subcloning of CyclinA2 and CDK2 to engineer MBP fusion proteins 
Preliminary expression and purification attempts for CyclinA2 resulted in precipitation of 
the protein. It has been reported that CyclinA2 can be successfully expressed in E. coli with the 
use of molecular folding chaperones (Grigoroudis et al., 2015). Furthermore, solubility of 
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expressed proteins with poor yield can be increased with the fusion of Maltose Binding Protein to 
the passenger protein within a pHMT vector (Figure 4a). Fusion of protein with MBP, along with 
a 6xHis metal affinity tag and TEV cleavage site allows for increased solubility and easy 
purification of the protein from the MBP-6xHis construct (Kapust & Waugh, 1999).  
DNA plasmids containing genes encoding the human CyclinA2 and Cyclin Dependent 
Kinase 2 proteins were received from Dr. Richard W. Kriwacki’s lab at St. Judes Children’s 
Hospital. The pHMT vector consisted of a 6xHis tag to aid in purification, a TEV cleavage site to 
sever the metal affinity tag and MBP from the protein of interest, and an MBP fusion protein, as 
well as a gene for Ampicillin resistance (Figure 4B). The protein insert would be ligated at the 
EcoRI and HindIII restriction digestion sites (Figure 4C).  
 
 
Figure 4: MBP fusion can increase solubility of proteins. A. Fusion of a passenger protein to 
MBP prevents insoluble aggregation of the protein of interest. Adapted from Kapust and Waugh, 
1999.  B. A pHMT vector can be used for expression of the protein of interest. MBP is fused to a 
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6xHis tag, and separated from the ligation point (marked by restriction enzyme sites of EcoRI 
and HindIII) by a TEV site. C. The expressed fusion protein includes the MBP protein, the TEV 
cleavage site, and the protein insert. 
 
2.1.1. Amplification of CyclinA2 and CDK2 by polymerase chain reaction 
PCR was performed with the CyclinA2 and CDK2 templates, and primers were designed 
to include the EcoRI restriction site on the forward primer, and the HindIII restriction site on the 
reverse primer (listed below).  
Primer Primer sequence, 5’ to 3’ 
CyclinA2 EcoRI forwards primer 5’ GGCGAATTCATGAATGAAGTACCAGACTAC 3’ 
CyclinA2 HindIII reverse primer 5’ GGCAAGCTTTTATTACAGATTTAGTGTCTC 3’ 
Cdk2 EcoRI forwards primer 5’ GGCGAATTCATGGAGAACTTTCAAAAG 3’ 
Cdk2 HindIII reverse primer 5’ GGCAAGCTTTTATTAGAGTCGAAGATG 3’ 
 
PCR amplification of the CyclinA2 and CDK2 inserts were verified via 1.5% agarose gel 
electrophoresis, and the samples were extracted and cleaned using the Nucleospin Plasmid Gel 
and PCR clean-up kit (Takara Bio). PCR reaction mixtures and conditions are listed below. 
Component Amount (total- 50µL) 




(10 mM, Thermofisher Scientific) 
1 µL 
10 µM Forwards Primer 2.5 µL 
10 µM Reverse Primer 2.5 µL 
Template DNA (~60 ng/µL) 0.5 µL 
Phusion DNA Polymerase  
(2000 units/mL, NEB) 
0.5 µL 





Initial denaturation 98℃, 30 seconds 
Cycles- 25X 98℃ for 10 sec, 59.5℃ for 30 sec, 72℃ for 1 
min 
Final extension 72℃ for 10 minutes 
 
2.1.2. Restriction digestion of PCR product 
The CyclinA2 and CDK2 PCR products were digested with EcoRI and HindIII at 37℃, 
before the enzymes were inactivated by heating to 80℃ for 30 minutes. Restriction digestion 
reaction mixture components are listed below.  
Component Amount (total- 30µL) 




(20,000 units/mL, NEB) 
1.5 µL 
EcoRI  
(20,000 units/mL, NEB)  
1.5 µL 
PCR product (55 nM)  20 µL 
Autoclaved water 4 µL 
 
2.1.3. Restriction digestion of pHMT vector 
The pHMT plasmid was isolated using the Nucleospin Plasmid EasyPure mini prep kit 
(Takara Bio), and digested with EcoRI and HindIII enzymes. Digestion was verified with 1.5% 
agarose gel electrophoresis. The restriction digestion reaction mixture for pHMT is listed below. 
Component Amount (total- 30 µL) 











10X cut-smart buffer 3 
 
2.1.4. Ligation and transformation 
The CyclinA2 and CDK2 gene constructs were ligated into the digested pHMT vector. 
Ligation products were transformed into electrocompetent E. coli DH5ɑ cells. Transformed cells 
were plated on an LB agar plate with 1 mM carbenicillin and grown overnight at 37℃. Colonies 
were selected, and the isolated plasmids were submitted for Sanger Sequencing with the forward 
and reverse primers c verify the presence of the correct target constructs. Absorbance of the 
digested pHMT plasmids and protein inserts was determined with the Nanodrop Microvolume 
Spectrophotometer (Thermofisher Scientific) at a wavelength of 260 nm. The Beer-Lambert law 
was used to extrapolate the concentration. Transformation components are listed below. 
Component Amount  
Digested pHMT 100 ng 
Insert 300 ng 







2.2. Expression of CyclinA2 and CDK2 protein 
The CyclinA2 and CDK2 constructs in the pHMT vector were transformed into E. Coli 
BL21-(DE3) cells. Single colonies were picked and grown in 1L of LB or M9 minimal media (66.7 
mM Na2HPO4, 1.32 mM KH2PO4, 18.35 mM 
15NH4Cl, 0.1 mM CaCl2, 2 mM MgSO4, 10 mL 
Gibco mix, 22.20 mM Glucose, 1 mL Trace metals mix, and 1 mM Carbenicillin). When grown 
in M9 minimal media, 15NH4Cl was the sole source of nitrogen for 
15N-labeling of the protein for 
NMR experiments. The cultures were grown at 37℃ until the OD measured between 0.6 and 0.8, 
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then induced with 1 mM IPTG and grown overnight at 24℃. Following overnight growth, cells 
were pelleted down by centrifugation (4193 G) and stored at -80℃. Protein expression was verified 
using SDS-PAGE by visualization with Coomassie blue dye.  
2.3. Purification of CyclinA2 protein 
For protein purification, cell lysis was performed by sonication in 25 mL of Lysis buffer 
(50 mM Tris (pH 8), 300 mM NaCl, 10 mM MgCl2, 10 mM TCEP, and 10% glycerol ) and 1 
cOmplete mini protease inhibitor cocktail tablet (EDTA-free, Millipore sigma). Sonication was 
performed for 14 minutes, at an amplitude of 50% with 5 seconds on and 2 seconds off in an ice 
bath. The mixture was then centrifuged for 45 minutes at 2696 G. 
The lysate was filtered (1.2µm, Milipore) and the protein was purified over a 5 mL IMAC 
nickel column (GE Healthcare). The wash buffer (buffer A) consisted of 10 mM Tris (pH 8), 10 
mM MgCl2, 25 mM Imidazole, 300 mM NaCl, and 10 mM TCEP. The elution buffer (buffer B) 
consisted of 10 mM Tris (pH 8), 10 mM MgCl2, 400 mM imidazole, 300 mM NaCl, and 10 mM 
TCEP. As the MBP-protein constructs included a 6xHis tag, the fusion protein bound to the nickel 
column in buffer A, before being eluted with a 10 column volume linear imidazole gradient using 
buffer B. During trials of buffer optimization and CyclinA2 purification, there was a large amount 
of impurities at each step, and there was evidence of CyclinA2 precipitation following removal of 
the MBP-6xHis tag construct upon cleavage by TEV protease. Consequently, further purification 
and complex formation used the MBP-CyclinA2 fusion protein.  
Following the first IMAC affinity column, ion-exchange chromatography was performed 
for further purification. The pooled fractions containing the protein of interest, which were 
identified using SDS-PAGE and Coomassie blue staining, were dialyzed (10 mM Tris- pH 6.5, 10 
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mM MgCl2, and 10 mM TCEP), then further purified with a 5 mL Hitrap Q-HP anion exchange 
column (GE Healthcare).  The wash buffer was the same as the dialysis buffer, and the elution 
buffer consisted of 10 mM Tris (pH 6.5), 10 mM MgCl2, 1 M NaCl, and 10 mM TCEP. After 
elution, fractions containing the protein of interest were identified using SDS-PAGE gel 
electrophoresis. As contaminants persisted in the fractions containing CyclinA2, size exclusion 
chromatography was performed using a Superdex 75 analytical column (Cytiva) in 50 mM Tris 
(pH 8), 10 mM MgCl2, 150 mM NaCl, and 10 mM BME.  
2.4. Purification of unlabeled CDK2  
Lysis buffer for unlabeled CDK2 consisted of 50 mM Tris (pH 8), 300 mM NaCl, 10% 
BME, 0.1% TritonX, and 10% glycerol. 25 mL of Lysis buffer and 1 cOmplete, mini protease 
inhibitor pellet (EDTA-free, Millipore sigma) were added to a pellet from a 1 L cell culture. 
Sonication, centrifugation and Nickel column purification steps were identical to CyclinA2 
purification. The wash buffer consisted of 50 mM Tris (pH 8), 25 mM Imidazole, 300 mM NaCl, 
and 10 mM TCEP. The elution buffer consisted of 50 mM Tris, 400 mM Imidazole, 300 mM NaCl, 
and 10 mM TCEP. The fractions containing MBP-CDK2 were identified with SDS-PAGE 
Coomassie blue staining, and digested using TEV protease at the cleavage site between CDK2 and 
MBP. TEV digestion was conducted overnight at room temperature, with a molar ratio of 1:25 for 
TEV protease to MBP-CDK2. The concentration of the MBP-CDK2 was determined using the 
Nanodrop Microvolume Spectrophotometer, at a wavelength of 280 nm, and the Beer-Lambert 
Law (ꜫ = 104,865 M-1 cm-1). Overnight dialysis was performed in 1L of the nickel column wash 
buffer. A second IMAC nickel column was performed with identical buffer conditions as the first, 
and the flowthrough collected. The presence of CDK2 in the flowthrough was verified using SDS-
PAGE and Coomassie staining.  
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The fractions containing cleaved CDK2 were purified using a 5 mL Hitrap Q-HP column 
(GE Healthcare). The pooled fractions were dialyzed overnight at 4℃ in 1 L of the Q-Sepharose 
wash buffer, consisting of 10 mM sodium phosphate (pH 6.6), and 10 mM TCEP. The elution 
buffer for the anion exchange column consisted of 10 mM sodium phosphate (pH 6.6), 1 M NaCl, 
and 10 mM TCEP. SDS-PAGE visualization with Coomassie blue staining confirmed the presence 
of CDK2 in the flowthrough, as well as a single contaminant. To completely purify CDK2, a S75 
preparatory size exclusion column was run (Cytiva) in 50 mM Phosphate (pH 8) + 150 mM NaCl 
+ 10 mM TCEP). SDS-PAGE visualization confirmed purification of CDK2. 
2.5 Purification of [U- 15N] CDK2 
For NMR spectroscopy, 15N CDK2 was expressed in the presence of 15NH4Cl as described 
in section 2.2. The IMAC columns and TEV cleavage steps in the purification process of 15N-
labeled CDK2 were identical to non-labeled CDK2, as detailed in section 2.4. Anion exchange 
chromatography was performed at an elevated pH of 8.0 (Wash buffer: 10 mM sodium phosphate 
(pH 8.0), and 10 mM TCEP. Elution buffer: 10 mM sodium phosphate (pH 8.0), 1 M NaCl, and 
10 mM TCEP). Following the anion exchange purification, fractions containing purified labeled 
CDK2 were combined and concentrated with a spin concentrator, until the molarity of the protein 
reached ~100 µM, measured by the Nanodrop spectrophotometer (Thermofisher Scientific) at 280 
nm and the Beer-Lambert Law. Upon concentration, some CDK2 precipitation was observed.   
2.6. Formation of CyclinA2 and CDK2 complex  
2.6. 1. CyclinA2 and CDK2 complex formation by direct mixing 
Multiple methodologies were used to form CyclinA2-CDK2. In the first method, 
approximately equimolar amounts of purified MBP-A2 and CDK2 were mixed at room 
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temperature, and then the complex was purified with a Superdex 200 analytical column (Cytivia). 
The buffer contained 50 mM Tris (pH 8), 10 mM MgCl2, 150 mM NaCl, and 10 mM BME. 
2.6.2. CyclinA2-CDK2 complex formation on a Ni2+ column 
Purified MBP-CyclinA2 was run through a 1 mL IMAC nickel column (GE Healthcare) 
and allowed to bind to the resin, before being treated with a wash buffer of 10 mM Tris (pH 8), 10 
mM MgCl2, 25 mM imidazole, 300 mM NaCl, 10 mM TCEP, and 1 mM ATP. A mixture of 
cleaved, purified, equimolar CDK2 and 1mM ATP was passed through the column. The column 
was left for 15 minutes to allow complex formation to occur between MBP-CyclinA2 and CDK2. 
The protein was eluted with a buffer consisting of 10 mM Tris, 10 mM MgCl2, 400 mM imidazole, 
300 mM NaCl, 10 mM TCEP, and 1 mM ATP. The presence of the proteins in fractions were 
analyzed using SDS-PAGE and Coomassie blue staining. Fractions containing the complex were 
digested overnight at room temperature with TEV at a ratio of 1:25. The digested complex was 
then diluted 10x, and run through another IMAC nickel column.  The flowthrough was pooled, 
concentrated, and purified using a Superdex75 analytical gel filtration column (50 mM Tris (pH 
8), 10 mM MgCl2, 150 mM NaCl, and 10 mM TCEP). SDS-PAGE visualization was used to 
determine the presence of the CyclinA2-CDK2 complex, which was confirmed with mass 
spectrometry. 
2.7. SDS-PAGE (protein gel electrophoresis) 
SDS-PAGE was used as an analytical tool in detecting protein presence in fractions 
following purification steps. SDS-PAGE was done using readymade gel and buffer (15% 




2.8. Native Mass Spectrometry 
Mass spectrometry can identify a molecule by measuring its molecular weight to a high 
degree of resolution. The analyte is converted to the gas phase, and an electrical charge is imparted. 
These charged ions are separated and identified using the mass-to-charge ratio, enabling the 
calculation of mass and relative abundance of different population states (Urban, 2016). Mass 
spectrometry was performed by Dr. Sophie Harvey at the CCIC facility, OSU. Samples were 
dialyzed into a buffer of 200 mM AmAc and analyzed by electrospray ionization on a Q Exactive 
UHMR instrument (Thermofisher Scientific).  
2.9. Nuclear magnetic resonance (NMR) spectroscopy 
Purified, [U-15N]-CDK2 was concentrated to approximately 100 µM (approximated due to 
slight precipitation) and dialyzed into NMR buffer (10 mM sodium phosphate (pH 8), 50 mM 
NaCl, and 5 mM BME. 10% of D2O and 1 µL DSS). NMR titrations were performed by Dr. 
Deepak Kumar Yadav. NMR titrations were performed with ATP and compounds 2-4 (Figure 3).  
Compounds 2-4 were titrated into CDK2 up to a ratio of approximately 1:2 of the inhibitor to the 
CDK2 protein (up to 200 µL). As the compounds were dissolved in DMSO, control spectra were 
collected of free CDK2 and CDK2 in the presence of 2% DMSO.  
 
3. Results 
3.1 Subcloning MBP-CyclinA2 and MBP-CDK2 vectors into the pHMT plasmid 
Soluble CyclinA2 and CDK2 proved difficult to isolate, therefore both proteins were 
subcloned into vectors containing an MBP fusion protein. The CyclinA2 and CDK2 PCR 
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amplification products were visualized with agarose gel electrophoresis, and product band sizes 
were confirmed with a molecular weight marker, indicating successful amplification (Figure 5A). 
Following restriction digestion with EcoRI and HindIII, the samples were used for ligation.  
Successful ligation of amplified, restriction enzyme digested CyclinA2 and CDK2 PCR 
products into pHMT vectors was verified by transformation into E. coli DH5ɑ electrocompetent 
cells, and the growth of colonies on LB agar plates supplemented with carbenicillin (Figure 5B). 
Sanger sequencing confirmed a 100% match of the CyclinA2 and CDK2 inserts into the pHMT 












Figure 5: Subcloning and transformation of CyclinA2 and CDK2  A. Agarose gel electrophoresis 
following PCR replication of the CyclinA2 and CDK2 inserts, which indicate PCR amplification 
product at the expected size. B. Colony growth following ligation and electroporation on agar 
plates with the (1) CyclinA2 insert, (2) CDK2 insert, (3) negative control of cells transformed 
with the digested vector, (4) and the positive control of cells transformed with the undigested 
pHMT plasmid. C. The chromatograms and sequencing of the transformed colonies indicated 
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successful subcloning of the CyclinA2 (Left) and CDK2 (Right) inserts, with 100% sequence 
alignment with the known DNA sequence.  
 
3.2 Protein expression 
3.2.1 Expression of MBP-CyclinA2 and MBP-CDK2  
MBP-CyclinA2 and MBP-CDK2 were optimally expressed at 24℃. This was visualized 
with SDS-PAGE and Coomassie blue staining (Figure 6A). Comparison between the induced and 
uninduced bands of the projected molecular weight following 1 mM IPTG induction showed 
successful protein expression at the expected molecular weight of 74.30 kDa for MBP-CyclinA2 
and 78.26 kDa for MBP-CDK2 (Figure 6B). Uniformly 15N-labeled CDK2 was expressed using 
minimal M9 media where 15N-ammonium chloride was provided as the sole nitrogen source.  
When comparing expression in minimal and in LB media, the band intensity of the induced protein 
was roughly equivalent, and the most intense band corresponded to the molecular weight of the 




          
 
Figure 6: SDS-PAGE gels of MBP-CyclinA2 and MBP-CDK2 expression. A. Expression tests of 
MBP-CyclinA2 at 16℃, 24℃, and 37℃. The most significant difference in band intensity can be 
seen in the 24℃ trial. B. Expression of MBP-CyclinA2 and MBP-CDK2 at 24℃. All 4 pellets 
show robust expression at the band corresponding to their theoretical mass of 74.3 kDa and 78.3 
kDa, respectively. C. Expression of 15N MBP-CDK2. Expression of labeled CDK2 is comparable 
to unlabeled CDK2, and there is robust expression, as indicated by the significant increase in 
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intensity at the band corresponding to the molecular mass of approximately 79.2 kDa. D. 
Protparam analysis of the MBP-CyclinA2, CyclinA2, MBP-CDK2, CDK2, and 6xHis constructs.  
 
3.3 Protein Purification 
3.3.1 MBP-CyclinA2 Purification 
Clarified lysate of MBP-CyclinA2 containing the 6xHistag on the MBP fusion protein was 
applied to an IMAC nickel column. Subsequent SDS-PAGE analysis indicated that a significant 
percentage of MBP-CyclinA2 had remained in the pellet. Similarly, there is a significant amount 
of MBP-CyclinA2 present in the flowthrough and wash steps, along with extreme amounts of 
contamination. The elution step of the affinity column resulted in more pure fractions, with a 
considerable amount of MBP-CyclinA2. Following anion exchange chromatography, SDS-PAGE 
revealed that while some impurities were removed, MBP-CyclinA2 still eluted with several 
contaminants. Between the elution of MBP-CyclinA2 from the IMAC column and further 
purification using gel filtration chromatography, MBP-CyclinA2 underwent degradation. 
Consequently, the size exclusion column load had an increase in impurities, particularly the 
concentration of the impurity weighing approximately 50 kDa, (Figure 7B Lane L). The SDS-
PAGE gel showed MBP-CyclinA2 to elute in peak 1, at 8.73 mL and slightly in peak 2, at 12.31 
mL (Figure 7B). Using a calibration curve derived from standards of known molecular weight, it 
became clear that the fusion protein was eluting at an apparent mass of 422.9 kDa and 143.4 kDa, 
as opposed to its theoretical mass of 72.3 kDa. This indicated dimeric and hexameric oligomer 




Figure 7: Oligomerization of MBP-CyclinA2. A. The chromatogram (280 nm) from an S75a size 
exclusion column showed three eluted peaks. The calculated molecular weights of each elution 
volume are listed in the Table above. B. SDS-PAGE shows a band corresponding to the theoretical 
size of MBP-CyclinA2 eluting in both peaks 1 and 2 (red box).  
 
3.3.2 Purification of Unlabeled CDK2 
The purification of MBP-CDK2 was successful and did not present the degradation 
problems which had persisted with MBP-CyclinA2. Analysis of the first IMAC nickel column 
with SDS-PAGE did not show a significant amount of MBP-CDK2 in the pellet, and the impurity 
of the sample caused difficulty when characterizing the relative amount of CDK2 in the lysate, 
flowthrough, and wash. While the elution step with high imidazole removed a significant portion 
of impurities compared to the purification of MBP-CyclinA2, there were still several contaminants 
present. TEV digestion was performed to remove the MBP-6xHis tag construct. Following 
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digestion, the sample was loaded and eluted from a second IMAC nickel column. SDS-PAGE 
analysis of the peak fractions showed CDK2 in the flowthrough, where it was expected to 
fractionate, and an additional peak during the linear imidazole gradient elution phase containing 
MBP, other contaminants, and the TEV protease. There was clear separation of most of the MBP 
folding chaperone from CDK2. However, several contaminants were still present, including a faint 
band at the molecular weight corresponding to MBP. These were present in far less quantities than 
CDK2. The anion-exchange column chromatogram indicated a plateaued peak where CDK2 eluted 
in the flowthrough, and a collection of peaks where MBP and other contaminants fractionated 
during the elution phase. SDS-PAGE analysis indicates almost complete purification of CDK2, 
except for a faint impurity corresponding to the molecular weight of the 6xHis-MBP construct.  
Prior to gel filtration chromatography, concentration of the pooled CDK2 fractions caused 
some precipitation (Figure 8, lane L). This final step partially separated CDK2 from the impurity, 
allowing for further analysis of both populations. Both CDK2 and the MBP contaminant, with 
theoretical molecular weights of 34.26 kDa and 44.02 kDa respectively, eluted under the same, 




Figure 8: Final purification step of CDK2.  The S75p chromatogram (280 nm) shows a singular, 
symmetric peak, in which both the CDK2 (blue square, 34 kDa) and MBP (red square, 44 kDa) 
contaminant eluted. The SDS-PAGE gel confirms this, and the MBP contaminant is only present 
in fractions 6 and 7. 
 
3.3.3 Purification on [U-15N]- CDK2  
Purification of 15N-CDK2 followed similar trends as the purification of the unlabeled 
protein. The chromatogram from the first nickel column showed a large peak eluting with the 
application of the high-imidazole buffer gradient. SDS-PAGE confirmed the peak to contain 
CDK2, however, there was a significant amount of CDK2 in the flowthrough and wash potentially 
due to overloading of the column. These fractions were pooled and run through an additional 
IMAC column, with the lower imidazole concentration in the loading buffer further separating the 
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contaminants in the wash and flowthrough from the protein, which bound to the column. SDS 
PAGE showed that more CDK2 had separated from the other impurities and could be pooled with 
the relevant fractions from the first nickel column. TEV protease was added to the fractions at a 
1:25 ratio, which cleaved almost all the MBP from CDK2. The ratio of 1:25 was chosen as trials 
with less TEV resulted in a large amount of un-cleaved fusion protein remaining following 
overnight digestion.  
The chromatogram from the anion exchange column showed a sustained plateau for the 
flowthrough, where CDK2 was expected to elute. A peak containing the remainder of the 
contaminants, including the MBP construct, eluted at a high concentration of NaCl (Figure 9, Lane 
E). Interestingly, the anion exchange chromatography step for the labeled protein, at a buffer of 
pH 8, was much more efficient in completely purifying CDK2 compared to the anion exchange 
column used in unlabeled CDK2 purification, performed at a pH of 6.6. Spin concentration was 
required and throughout the concentrating process CDK2 slightly precipitated, resulting in a white 
hue to the solution. The concentration was determined using the Beer-Lambert law and the 




Figure 9: Final purification step of 15N CDK2. Anion exchange chromatography was the final step 
in purifying 15N CDK2. The chromatogram shows a sustained plateau during the loading step, in 
which the pure CDK2 is collected in the flowthrough. A large peak at the elution step of the 
chromatogram, and the right-most lane on the SDS-PAGE gel, corresponds to the elution of the 
MBP construct, as well as all other contaminants. 
 
3.4 Complex formation 
3.4.1. Complex Formation by Mixing 
The mixing of CDK2 and MBP-CyclinA2 did not form a singular complex, as evident by 
the elution of two distinct peaks on a size exclusion column, one of which corresponding to 




Figure 10: Gel filtration of mixing CDK2 and MBP-CyclinA2. Mixing equimolar amounts of 
CDK2 and MBP-CyclinA2 prior to purification with size exclusion chromatography resulted in 
the elution of 2 distinct peaks, neither of which corresponded to the calculated molecular weight 
of the complex.  
 
 
3.4.2. Complex Formation by Nickel column 
Complex formation in a nickel column was attempted by allowing MBP-CyclinA2 to bind 
to the resin, then adding CDK2. Binding would occur within the column, and the complex would 
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elute in the same fraction with the application of the elution buffer. An SDS-PAGE gel was run 
following the complex formation by nickel column. The MBP-CyclinA2 load can be seen to have 
multiple contaminants (Figure 11A, lane 1), while the CDK2 loads are almost devoid of impurities 
(Figure 11A, Lane 2). A band corresponding to CDK2 can be seen in the flowthrough fractions 
(Figure 11A, Lane 5). However, this is a much fainter band than the initial load. MBP-CyclinA2, 
CDK2, and several impurities eluted in the same fraction, indicating that they eluted 
simultaneously (Figure 11A, lane 6). Following TEV digestion, and a second nickel column 
purification, SDS-PAGE displayed both bands corresponding to the CyclinA2 and CDK2 proteins 
in the flowthrough (Figure 11B, Lane 3). In the same elution fraction as MBP, there is still an 
amount of undigested MBP-CyclinA2. Concentration of the flowthrough yielded a fraction with 
one major contaminant, which was removed using size exclusion chromatography, and the purity 
was confirmed with SDS-PAGE gel electrophoresis (Figure 11C). Native mass spectrometry 
identified a species with an experimentally determined mass that was similar to the theoretical 







Figure 11: Formation of the CyclinA2-CDK2 complex. A. The SDS-PAGE gel for the first nickel 
column fractions, with the steps associated with each lane listed below. The presence of the band 
corresponding to the molecular weight of CDK2 in the same elution step as MBP-CyclinA2 
indicates complex formation (red square). B. SDS-PAGE gel following TEV digestion and 
removal of the MBP construct. The steps corresponding to each lane are listed below. There is 
evidence of CyclinA2 and CDK2 in the flowthrough (red square). C. SDS-PAGE of the size 
exclusion run. The load (L), elution (E), and pre-stained marker (M) are labeled. D. Native mass 
spectrometry yields signals corresponding to the CyclinA2-CDK2 complex.  
 
3.4.3 Native Mass Spectrometry of CDK2 
Native mass spectrometry was conducted on unlabeled and 15N-labeled CDK2 to verify the 
identity of the purified protein by size. Native mass spectrometry revealed multiple population 
states of CDK2 in both 15N labeled and unlabeled samples. Peaks were identified which 
corresponded to the mass of unbound CDK2, phosphorylated CDK2, CDK2 bound to adenosine, 
and phosphorylated CDK2 bound to adenosine. With the addition of ATP, the same four states 
persisted, and there were no additional peaks identified corresponding to the molecular weight of 





Figure 12: Mass spectrometry revealed multiple population of CDK2. In both unlabeled and 15N-
labeled CDK2, four population states were observed, most clearly visualized at the 11+ charge 
state.   
 
3.4.4 NMR spectroscopy 
Purified [U-15N]-CDK2 was concentrated up to 100 µM, and slight precipitate was noted 
in the sample, as evident by a milky white layer in the bottom of solution. This made exact 
quantification of CDK2 concentration impossible, but approximately 100 µM CDK2 was used for 
each titration.  
Due to the absence of published backbone chemical shift assignments of CDK2, 15N-HSQC 
peaks could not be assigned to their respective residues. However, general observations can be 
made about the free CDK2 protein based on the quality of the 15N-HSQC spectrum (Figure 13A). 
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Most of the peaks look well resolved and distributed across the spectrum, indicating a well folded 
CDK2 protein. Using this spectrum as a reference, qualitative observations were made about 
interactions between CDK2 and the compounds, as well as ATP.  
To ensure that the presence of DMSO was note responsible for the observed changes in the 
spectrum, a control experiment of CDK2 in the presence of 2% DMSO was recorded. An overlay 





Figure 13: HSQC Titration Controls: A. HSQC spectrum of CDK2. The spectrum looks well 
resolved, and the protein appears to be folded. B. DMSO control. Overlaying the spectrum of free 
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CDK2 and CDK2 + 2% DMSO does not show significant CSP, indicating that it will not be a 
confounding variable. 
 
Addition of higher concentrations of ATP (200 µM and 1 mM) in the presence of 
magnesium resulted in significant increases in chemical shift perturbations (Figure 14). 
 
 
Figure 14: titration of CDK2 with ATP in the presence of magnesium. The 15N-HSQC spectra of 
free CDK2 (190 µM), CDK2 + ATP (190 µM), CDK2 + Mg2+ (190 µM)  + ATP (190 µM), CDK2 
+ Mg2+ (190 µM) + ATP (380 µM), and CDK2 + Mg2+ (190 µM ) + ATP (1.9 mM) are overlayed. 
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Peaks with significant chemical shift perturbations are marked with an arrow, pointing in the 
direction of the shifts from free CDK2 to ATP bound CDK2.  
The Titration with Compound 2: In comparison to the other inhibitors and ATP, compound 2 was 
observed to have the largest impact in chemical shift perturbations. These chemical shift 
perturbations progress in a step-wise fashion as the concentration of the compound increased to 
200 µM (Figure 15A). However, addition of magnesium did not lead to any significant CSP 
(Figure 15B), which indicates that magnesium is not required for interaction between compound 
2 and CDK2.  
Titration of Compound 3: Stepwise chemical shift perturbations can be seen with throughout the 
compound 3 titration with CDK2. Similar to compound 2, backbone CSP of the CDK2 protein 
with addition of compound 3 indicates that the protein interacts with the inhibitor (Figure 15C). 
The addition of magnesium produced similar results to the trial with compound 2 and did not cause 
additional peak shifting. This indicated that CDK2 does not require magnesium as a prerequisite 
for binding to compound 3. 
Titration of Compound 4: The titration of compound 4 into CDK2 caused progressive chemical 
shift perturbations, similar to compounds 2 and 3 (Figure 15D). CSPs in the HSQC titration 














Figure 15: NMR spectra of CDK2 in absence and presence of varying concentrations of ligand. A. 
Titration of compound 2 into CDK2. The spectra of free CDK2 (150 µM), and CDK2 + compound 
2 at concentrations of 52 µM, 104 µM, 150 µM, and 200 µM are overlayed. B. The spectra pictured 
in figure 15A is overlayed with the spectra of CDK2 + compound 2 (200µM) + Mg2+ (400µM) 
There is not a significant amount of additional chemical shift perturbations. Addition of 
magnesium to the CDK2 + compound 3 titration similarly resulted in few CSP. C. Titration of 
compound 3 into CDK2. The spectra of free CDK2 (90 µM), CDK2 + compound 3 at 
concentrations of 42 µM, 100 µM, and 150 µM are overlayed. D. Titration of compound 4 into 
CDK2. The spectra of free CDK2 (75 µM, CDK2 + compound 4 at concentrations of 42 µM, 100 
µM, and 150 µM are overlayed. In A, C, and D, peaks with significant chemical shift perturbations 
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are marked with an arrow, pointing in the direction of the chemical shift from free CDK2 to CDK2 
bound to each compound. 
 
4. Discussion 
4.1 Expression and purification of proteins 
The decision to include MBP as a fusion protein stemmed from its ability to increase 
solubility and therefore yield of protein, the mechanism of which is predicted to be by passively 
inhibiting aggregation pathways (Waugh, 2016). The aggregation of CyclinA2 is characteristic of 
some eukaryotic proteins, which may form insoluble inclusion bodies when expressed in E. coli. 
Prokaryotic cellular conditions are different than eukaryotic, and the prokaryotic cell cannot 
complete necessary post-translational modifications, potentially resulting in an incomplete or mis-
folded protein. 
While SDS-PAGE is a powerful tool in determining the presence and relative purity of the 
target protein, the reducing agent present in the loading dye dissolved the MBP-CyclinA2 soluble 
aggregates by reducing cysteine-cysteine bonds. Consequently, throughout purification steps, it 
appeared that MBP-CyclinA2 was monomeric in solution. However, size exclusion, which allows 
visualization of the molecular weight in native conditions, showed oligomerization of MBP-
CyclinA2 into approximately a hexamer and a dimer. MBP-CyclinA2 seemed to undergo 
degradation, even when stored at 4℃. The degradation of MBP-CyclinA2, paired with the poor 
yield due to instability of CyclinA2, presented substantial difficulties in purification.  
In the purification of both labeled and unlabeled CDK2, the 6xHis-MBP contaminant 
persisted, however it was present in a higher relative concentration with the 15N labeled CDK2. 
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This presented difficulties in purifying a sample enough to conduct NMR.  Theoretically, as the 
fusion protein had bound to the nickel-coated resin in the initial affinity column, the cleaved 6xHis-
MBP construct should have bound to the second affinity column as well. Potential causes as to the 
presence of the impurity in the flowthrough include interactions between the cleaved MBP 
construct and CDK2 following the TEV treatment. In size exclusion chromatography, the MBP 
contaminant persisted. This is not unsurprising, as the size difference between the construct and 
CDK2 is only roughly 10 kDa. There is a small degree of separation, however, as the MBP 
contaminant eluted in the second collected fraction only. Interestingly enough, the general pattern 
of size exclusion chromatography dictates that an increase in elution volume corresponds to a 
decrease in molecular weight, suggesting that the MBP construct behaved as a protein with a 
smaller molecular weight than CDK2. Potential reasons for this discrepancy could be the shape of 
MBP, affecting intercalation through the resin. If MBP was globular or compact enough, it might 
behave as a smaller protein. Opposingly, CDK2’s bi-lobar structure could have caused it to behave 
as a larger protein.  
For CDK2 purification, anion exchange chromatography was used to remove the MBP 
impurity. The theoretical pIs of CDK2 and the MBP construct are 8.61 and 5.32, respectively. 
Therefore, the first anion exchange purification step was completed at pH 6.6, with the expectation 
that the MBP construct would interact with the positively charged resin, while CDK2 would elute 
in the flowthrough. Puzzlingly, following this step there was still the MBP contaminant present in 
the sample. For the 15N labeled CDK2 purification, anion exchange chromatography was 
performed at pH 8.0, in attempt to maximize MBP binding to the column. In these conditions, 
separation of the MBP contaminant was absolute. This implies that the theoretical pI of the MBP 
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construct may not have been accurate in the presence of CDK2, as it behaved like a protein with a 
more elevated pI.  
 
4.2 Native Mass Spectrometry of CDK2  
Native mass spectrometry showed the same four population states for both 15N-labeled and 
unlabeled CDK2, and in varying conditions of magnesium and ATP. There is a conserved 
phosphorylation point on CDK2 at Thr160, which must be phosphorylated following CyclinA2 
binding for activation of the complex. However, this phosphorylation site is usually buried until 
the CDK has undergone the conformational change associated with Cyclin binding. 
Phosphorylation could still occur, as there are additional inhibitory phosphorylation sites on 
CDK2, and some evidence that the activation loop containing  the phosphorylation site at Thr160 
may be flexible enough to allow for phosphorylation before Cyclin binding (Desai, et al. 1995). 
The molecular weight of the third and fourth CDK2 population states correspond to CDK2 and 
phosphorylated CDK2 bound to adenosine. Since CDK2 binds ATP, the ligand binding site could 
facilitate a lone adenosine base. Additionally, efforts to dislodge adenosine by repeating the mass 
spectrometry with a 1:1 ratio of CDK2 and ATP in the presence of magnesium did not result in 
the expected corresponding peaks. A potential reason for this is the sample is dialyzed into a buffer 
of 200 mM AmAc just before collecting native mass spectrometry data. It is possible that the ATP 
was dialyzed out of the sample. Further trials with the addition of ATP and magnesium after 
dialysis are required to fully understand the behavior of CDK2 binding to ATP.  
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For all three samples, while the population states are all present, they are different in their 
relative abundance. In both15N spectra, the phosphorylated states decreased in relative abundance, 
and the adenosine-bound states increased in abundance.  
 
 
4.7 HSQC NMR of CDK2 
Compounds 1, 2, 3, and 4 dissolved in 100% DMSO were received from Dr. Jose Otero’s 
lab. DMSO, an organic solvent, is necessary to dissolve nonpolar organic compounds, but can 
cause denaturation of proteins at a high concentrations (Abraham et al., 2006). Consequently, the 
presence of DMSO at higher concentrations can cause chemical shift perturbations in 15N-HSQC 
NMR experiments. To minimize the effect of DMSO on protein folding and stability, 15N-HSQC 
NMR experiments were performed in the presence of 2% DMSO. As the overlay of the spectra 
shows minimal CSP, the presence of DMSO in the buffer can be disregarded as a potential 
confounding variable.  
Chemical shift perturbations of CDK2 increased in magnitude with a higher concentration 
of ATP and in the presence of magnesium. This indicates that magnesium may be required for 
ATP binding, and is supported by literature (Bao et al., 2011).  The noticeable CSP in 15N-HSQC 
NMR experiments are present even with a 3:1 ratio of CDK2 to compound 2. This indicates that 
CDK2 is binding with stronger affinity relative to ATP. Furthermore, these step-wise shifts occur 
prior to the addition of magnesium, and the addition of magnesium does not cause any additional 
CSP. This suggests that, unlike ATP, CDK2 may not require magnesium to bind to compound 2.  
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Similarly, significant CSPs are observed in 15N-HSQC NMR experiments of CDK2 titrations with 
compound 3 in absence of magnesium.   
Interestingly, the comparison of the CDK2 titrations with ATP and the different 
compounds showed some similarities. While the direction and magnitude of the chemical shifts 
varied from spectrum to spectrum, the identity of many of the peaks affected was uniform (Figure 
16C). This indicates that ATP and the compounds interacted with CDK2 in a similar fashion, at 
the ATP binding cleft. This is somewhat unsurprising, as the structures of the compounds are 
similar to ATP, including a carbohydrate moiety and the linked 5 and 6 atom rings that are 
structurally similar to adenosine (Figure 16B). In addition, it appears that by comparing 15N-HSQC 
of CDK2 at concentrations of 200 µM for the compounds and 1 mM for ATP, the magnitude of 
the amide peak shift was on average much greater in presence of the compounds (Figure 16A). 
This suggests that CDK2 has a greater affinity for the compounds than for ATP. This is consistent 
with literature and the preliminary results, as the inhibitors were found to have an IC50 in the 
nanomolar to micromolar range (Stephanie Kim et al., 2020), and the Kd for ATP is 17 µM (Morris 





Figure 16: In all titrations, many of the same peaks experienced significant CSPs. A. A collection 
of peaks in which free CDK2 (black) is overlayed with all titrations: CDK2 with ATP (cyan), 
compound 2 (blue) , compound 3 (red), and compound 4 ( green). The titrated peaks displayed 
significant CSPs. Arrows display the general direction of the CSPs from the free CDK2 spectra. 
B. The chemical structures of ATP and the 3 compounds. The 3 compounds have similar chemical 
structures to ATP, with a 2-ring base and pentose forming the main structure. C. Many of the peaks 
experiencing CSPs were uniform in all the compounds tested. The 20 most significant chemical 
shift perturbations in the ATP titration were compared with the compound titrations. The 






In conclusion, while CDK2 was purified successfully, the aggregation of MBP-CyclinA2 
made it impossible to test the effect of the inhibitors on independent CyclinA2, or the CDK2-
CyclinA2 complex. CDK2 has interactions with compounds 2, 3, and 4. The similarities in which 
peaks experienced amide chemical shift perturbations when compared to the ATP titration 
suggests that these compounds competitively inhibit the ATP binding site. Additionally, the 
inhibitors, specifically compound 2, appear to cause larger chemical shift perturbations than ATP, 
indicating that CDK2 may bind more tightly to the inhibitors. Currently, none of these compounds 
are labeled as being CDK2 inhibitors in the NSC database. In a broader pharmacological 
perspective, these compounds may not be as therapeutically promising as inhibitors which interact 
with the CDK2 allosteric site, as the ATP binding cleft is highly conserved in the CDK family, 
and specificity would be limited. However, this high degree of homology suggests that these 
compounds may also be inhibitory to other members of the CDK family.  
While these inhibitors interact with CDK2, it is unclear whether they also act by binding 
to the allosteric site on CyclinA2, or to the CyclinA2-CDK2 complex. Furthermore, it is unknown 
how compound 1 interacts with CDK2, as it was not tested. Structurally, compound 1 is not as 
similar to ATP compared to compounds 2, 3, and 4 (Figure 3), so it would be interesting to 
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